Patents Assigned to Saitama Medical University
-
Patent number: 11859006Abstract: This application relates to a pharmaceutical composition for use in a method for treating and/or preventing a patient having ectopic ossification and/or brain tumor, wherein the patient has an active mutation in ALK2 protein which is responsible for ectopic ossification or brain tumor; an amino acid residue at position 330 of ALK2 is proline; and an active ingredient of this composition is an anti-ALK2 antibody or an antigen-binding fragment thereof comprising a property of binding to ALK2, a property of cross-linking ALK2, and a property of inhibiting BMP signal transduction.Type: GrantFiled: March 4, 2019Date of Patent: January 2, 2024Assignees: Saitama Medical University, Daiichi Sankyo Company, LimitedInventors: Takenobu Katagiri, Sho Tsukamoto, Keigo Kumagai, Shinnosuke Tsuji
-
Patent number: 11447554Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).Type: GrantFiled: October 26, 2021Date of Patent: September 20, 2022Assignees: Saitama Medical University, Daiichi Sankyo Company, LimitedInventors: Takenobu Katagiri, Kenji Osawa, Sho Tsukamoto, Shinnosuke Tsuji, Yoshirou Kawaguchi, Kensuke Nakamura
-
Publication number: 20220267453Abstract: This application provides: an antibody or an antigen-binding fragment thereof which can be used not only as a therapeutic drug but as a tool of immunological and immunohistological analysis such as immunostaining or Western blot, specifically recognizes an extracellular region polypeptide of human, mouse and rat ALK2, and inhibits BMP signal transduction, and an antibody or an antigen-binding fragment thereof which has a property of specifically binding to an extracellular region of ALK2 to form an ALK2 homodimer and a property of inhibiting the formation of an ALK2-type II receptor heterodimer, and inhibits the activation of ALK2 kinase, or inhibits BMP signal transduction; and a method for inhibiting the activation of ALK2 kinase or a method for inhibiting BMP signal transduction using the antibody or the antigen-binding fragment thereof.Type: ApplicationFiled: July 22, 2020Publication date: August 25, 2022Applicants: Saitama Medical University, Daiichi Sankyo Company, LimitedInventors: Takenobu KATAGIRI, Sho TSUKAMOTO, Mai KURATANI
-
Patent number: 11312776Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).Type: GrantFiled: August 19, 2019Date of Patent: April 26, 2022Assignees: Saitama Medical University, Daiichi Sankyo Company, LimitedInventors: Takenobu Katagiri, Kenji Osawa, Sho Tsukamoto, Shinnosuke Tsuji, Yoshirou Kawaguchi, Kensuke Nakamura
-
Patent number: 11293924Abstract: The present invention relates to the prediction of responsiveness to cancer immunotherapy of a subject based on the T-cell composition of the subject, and a therapeutic method using cancer immunotherapy based on the prediction. The present invention also provides a method for improving or maintaining responsiveness to cancer immunotherapy of a subject. Responsiveness to cancer immunotherapy is predict by determining a relative value of a CD4+ T-cell subpopulation, dendritic cell subpopulation, and/or CD8+ T-cell subpopulation correlated with a dendritic cell stimulation in an anti-tumor immune response in a sample derived from a subject. A composition for treating or preventing cancer comprising cells such as CD62LlowCD4+ T-cells is also provided.Type: GrantFiled: February 6, 2018Date of Patent: April 5, 2022Assignee: Saitama Medical UniversityInventor: Hiroshi Kagamu
-
Publication number: 20220041738Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).Type: ApplicationFiled: October 26, 2021Publication date: February 10, 2022Applicants: Saitama Medical University, Daiichi Sankyo Company, LimitedInventors: Takenobu KATAGIRI, Kenji OSAWA, Sho TSUKAMOTO, Shinnosuke TSUJI, Yoshirou KAWAGUCHI, Kensuke NAKAMURA
-
Patent number: 10994007Abstract: Disclosed is an immunity inducer. The immunity inducer comprises virus like particles; the virus like particles comprise a virus-derived outer coat protein and an antigen-bound protein comprising an exogenous antigen; the outer coat protein constitutes an outer coat of the virus like particles, and the antigen-bound protein is comprised in the outer coat; and the virus like particles induce an immune effect of a living body on the antigen.Type: GrantFiled: November 29, 2016Date of Patent: May 4, 2021Assignees: Saitama Medical University, SYSMEX CORPORATIONInventors: Hiroshi Handa, Masaaki Kawano, Masahiko Kato
-
Publication number: 20210009709Abstract: This application relates to a pharmaceutical composition for use in a method for treating and/or preventing a patient having ectopic ossification and/or brain tumor, wherein the patient has an active mutation in ALK2 protein which is responsible for ectopic ossification or brain tumor; an amino acid residue at position 330 of ALK2 is proline; and an active ingredient of this composition is an anti-ALK2 antibody or an antigen-binding fragment thereof comprising a property of binding to ALK2, a property of cross-linking ALK2, and a property of inhibiting BMP signal transduction.Type: ApplicationFiled: March 4, 2019Publication date: January 14, 2021Applicants: SAITAMA MEDICAL UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Takenobu KATAGIRI, Sho TSUKAMOTO, Keigo KUMAGAI, Shinnosuke TSUJI
-
Patent number: 10851342Abstract: The present invention allows a TET1 protein to be more stably expressed in human pluripotent stem cells than in the past by, inter alia, substituting the second amino acid from the amino terminal of a TET1 protein with a different amino acid. Furthermore, upon differentiation of said pluripotent stem cells, it is possible to quickly eliminate the expression of, inter alia, NANOG, which is an inhibitor of differentiation and promote the expression of factors related to differentiation by introducing a variant TET1 protein to a pluripotent stem cell. The present invention provides a method for manufacturing pluripotent stem cells with increased differentiation potential, and a substance that is useful to said method.Type: GrantFiled: December 14, 2017Date of Patent: December 1, 2020Assignee: Saitama Medical UniversityInventors: Hidemasa Kato, Yosuke Moriyama, Keiko Hiraki, Akihiko Okuda
-
Patent number: 10835551Abstract: A double-stranded nucleic acid molecule for suppressing expression of non-coding RNA, the double-stranded nucleic acid molecule including: (a) a sense strand containing a nucleotide sequence corresponding to a target sequence set forth in any one of SEQ ID NOs: 26 to 31; and (b) an antisense strand containing a nucleotide sequence which is complementary to the sense strand in the (a) to form a double strand with the sense strand, wherein the non-coding RNA contains a base sequence set forth in any one of SEQ ID NOs: 2 to 4, a part of the base sequence, or both of the base sequence and the part.Type: GrantFiled: January 2, 2020Date of Patent: November 17, 2020Assignee: SAITAMA MEDICAL UNIVERSITYInventors: Satoshi Inoue, Kazuhiro Ikeda, Kuniko Inoue
-
Patent number: 10809200Abstract: Provided is a test object visualizing device, including: light irradiating unit configured to make wavelength of at least any one of pump light and Stokes light generated on the same optical path variable per test position of test object, and irradiate test object with pump light and Stokes light; molecule distribution image generating unit configured to detect anti-Stokes light emitted from test object according to wavelength difference between pump light and Stokes light, and generate a molecule distribution image based on anti-Stokes light; tomographic image generating unit configured to detect at least any one of reflected light from test object when irradiated with pump light and reflected light from test object when irradiated with Stokes light, and generate a tomographic image of test object based on the reflected light detected; and image display unit configured to display at least any one of molecule distribution image and tomographic image generated.Type: GrantFiled: June 16, 2017Date of Patent: October 20, 2020Assignee: SAITAMA MEDICAL UNIVERSITYInventor: Masahiro Toida
-
Publication number: 20200121710Abstract: A double-stranded nucleic acid molecule for suppressing expression of non-coding RNA, the double-stranded nucleic acid molecule including: (a) a sense strand containing a nucleotide sequence corresponding to a target sequence set forth in any one of SEQ ID NOs: 26 to 31; and (b) an antisense strand containing a nucleotide sequence which is complementary to the sense strand in the (a) to form a double strand with the sense strand, wherein the non-coding RNA contains a base sequence set forth in any one of SEQ ID NOs: 2 to 4, a part of the base sequence, or both of the base sequence and the part.Type: ApplicationFiled: January 2, 2020Publication date: April 23, 2020Applicant: Saitama Medical UniversityInventors: Satoshi INOUE, Kazuhiro IKEDA, Kuniko INOUE
-
Patent number: 10561679Abstract: A double-stranded nucleic acid molecule for suppressing expression of non-coding RNA, the double-stranded nucleic acid molecule including: (a) a sense strand containing a nucleotide sequence corresponding to a target sequence set forth in any one of SEQ ID NOs: 5 to 11 and 26 to 31; and (b) an antisense strand containing a nucleotide sequence which is complementary to the sense strand in the (a) to form a double strand with the sense strand, wherein the non-coding RNA contains a base sequence set forth in any one of SEQ ID NOs: 1 to 4, a part of the base sequence, or both of the base sequence and the part.Type: GrantFiled: June 12, 2015Date of Patent: February 18, 2020Assignee: SAITAMA MEDICAL UNIVERSITYInventors: Satoshi Inoue, Kazuhiro Ikeda, Kuniko Inoue
-
Publication number: 20200002427Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).Type: ApplicationFiled: August 19, 2019Publication date: January 2, 2020Applicants: SAITAMA MEDICAL UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: TAKENOBU KATAGIRI, KENJI OSAWA, SHO TSUKAMOTO, SHINNOSUKE TSUJI, YOSHIROU KAWAGUCHI, KENSUKE NAKAMURA
-
Patent number: 10428148Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).Type: GrantFiled: January 29, 2016Date of Patent: October 1, 2019Assignees: Saitama Medical University, Daiichi Sankyo Company, limitedInventors: Takenobu Katagiri, Kenji Osawa, Sho Tsukamoto, Shinnosuke Tsuji, Yoshirou Kawaguchi, Kensuke Nakamura
-
Patent number: 10413559Abstract: It is an object of the present invention to provide a novel therapeutic agent for demyelinating disease which has an action to suppress demyelination of nerve axons. According to the present invention, a therapeutic agent for demyelinating disease which comprises cyclic phosphatidic acids, carba-cyclic phosphatidic acids, thia-cyclic phosphatidic acids, or a salt thereof is provided.Type: GrantFiled: January 28, 2014Date of Patent: September 17, 2019Assignees: OCHANOMIZU UNIVERSITY, SAITAMA MEDICAL UNIVERSITYInventors: Kimiko Murofushi, Mari Gotoh, Kei Maruyama, Keisuke Yoshikawa, Shinji Yamamoto
-
Patent number: 10370730Abstract: A method for detecting a mutation in an amino acid at position 93 of a hepatitis C virus NS5A protein, the method including: synthesizing cDNA using, as a template, hepatitis C virus RNA in a sample; and performing a real-time PCR with a cycling probe method using, as a template, the cDNA; wherein a primer set used in the real-time PCR is a certain primer set; and wherein probes used in the real-time PCR include certain probes.Type: GrantFiled: December 11, 2014Date of Patent: August 6, 2019Assignee: SAITAMA MEDICAL UNIVERSITYInventors: Satoshi Mochida, Yoshihito Uchida, Jun-ichi Kouyama, Kayoko Naiki
-
Patent number: 10369218Abstract: Disclosed is an immunostimulator containing virus-like particles, in which the virus-like particles contain an outer coat protein containing an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 26, SEQ ID No. 33, SEQ ID No. 35, SEQ ID No. 37, SEQ ID No. 39, SEQ ID No. 41, SEQ ID No. 43 and SEQ ID No. 45; the outer coat protein constitutes an outer coat of the virus-like particles; and the virus-like particles do not substantially contain a genome DNA of SV40.Type: GrantFiled: December 22, 2016Date of Patent: August 6, 2019Assignees: Saitama Medical University, SYSMEX CORPORATIONInventors: Hiroshi Handa, Masaaki Kawano, Masahiko Kato
-
Publication number: 20190189260Abstract: A method of evaluating a therapeutic effect of a drug in a cancer patient, comprising a comparison step of comparing a first absolute hemoglobin concentration in a sternum portion of the cancer patient before administration of the drug and a second absolute hemoglobin concentration in the sternum portion of the cancer patient after administration of the drug; and an evaluation step of evaluating the therapeutic effect of the drug in the cancer patient based on the result of comparison performed through the comparison step.Type: ApplicationFiled: August 8, 2017Publication date: June 20, 2019Applicants: SAITAMA MEDICAL UNIVERSITY, HAMAMATSU PHOTONICS K.K.Inventors: Shigeto UEDA, Toshiaki SAEKI, Yukio UEDA
-
Publication number: 20190137402Abstract: Provided is a test object visualizing device, including: light irradiating unit configured to make wavelength of at least any one of pump light and Stokes light generated on the same optical path variable per test position of test object, and irradiate test object with pump light and Stokes light; molecule distribution image generating unit configured to detect anti-Stokes light emitted from test object according to wavelength difference between pump light and Stokes light, and generate a molecule distribution image based on anti-Stokes light; tomographic image generating unit configured to detect at least any one of reflected light from test object when irradiated with pump light and reflected light from test object when irradiated with Stokes light, and generate a tomographic image of test object based on the reflected light detected; and image display unit configured to display at least any one of molecule distribution image and tomographic image generated.Type: ApplicationFiled: June 16, 2017Publication date: May 9, 2019Applicant: Saitama Medical UniversityInventor: Masahiro TOIDA